Stockscreener 앱 받기
0.903
0.30%
0.0027
시간 외 거래:
.91
0.007
+0.78%
전일 마감가:
$0.9003
열려 있는:
$0.89
하루 거래량:
288.93K
Relative Volume:
0.06
시가총액:
$17.66M
수익:
-
순이익/손실:
$-33.04M
주가수익비율:
-0.0992
EPS:
-9.1023
순현금흐름:
$-39.66M
1주 성능:
-0.77%
1개월 성능:
-21.48%
6개월 성능:
-97.57%
1년 성능:
-93.36%
1일 변동 폭
$0.8845
$0.9432
1주일 범위
$0.8845
$0.9953
52주 변동 폭
$0.79
$45.50
Quince Therapeutics Inc Stock (QNCX) Company Profile
명칭
Quince Therapeutics Inc
전화
415-910-5717
주소
611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO
Compare QNCX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
QNCX
Quince Therapeutics Inc
|
0.903 | 18.21M | 0 | -33.04M | -39.66M | -9.1023 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Quince Therapeutics Inc Stock (QNCX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-30 | 다운그레이드 | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2025-08-05 | 개시 | Citizens JMP | Mkt Outperform |
| 2025-03-24 | 개시 | Oppenheimer | Outperform |
Quince Therapeutics Inc 주식(QNCX)의 최신 뉴스
Quince Therapeutics (QNCX) director granted stock options for 2,700 shares - Stock Titan
Quince Therapeutics (QNCX) director receives 2,700 stock options grant - Stock Titan
Number of shareholders of Quince Therapeutics, Inc. – NASDAQ:QNCX - TradingView
QUINCE THERAPEUTICS INC (QNCX) Stock Chart - ChartMill
Quince Therapeutics (QNCX) Approves Reverse Stock Split—SEC 8-K Filing Details (June 11, 2026) - Minichart
Quince Therapeutics (QNCX) officer awarded multi-million share option grants - Stock Titan
Quince Therapeutics (NASDAQ: QNCX) files Form 3 for officer Brigette Roberts - Stock Titan
Quince Therapeutics (NASDAQ: QNCX) wins approval for wide reverse split range - Stock Titan
Quince Therapeutics, Inc. announced that it has received $115.000298 million in funding from a group of investors - marketscreener.com
[SCHEDULE 13G] Quince Therapeutics, Inc. Passive Investment Disclosure (>5%) - Stock Titan
QNCX Q1 2026 Earnings: Unexpected Profit Driven by One-Time Items; Shares DipSurprise Factor Analysis - newsline.com
Quince Therapeutics Inc. (QNCX) Q1 2026 Earnings: Massive EPS Surprise Driven by Non-Operating Items, Stock DeclinesNet Profit Margin - newsline.com
Quince Therapeutics Inc. (QNCX) Presents Positive Phase 2a Data for LAM-001 Inhaled Therapy - Insider Monkey
5 Popular Penny Stocks on Robinhood to Watch in 2026 - Insider Monkey
Quince Therapeutics stock (US74833Q1004): Nasdaq-listed biotech rebounds after regaining compliance - AD HOC NEWS
Why is QNCX stock up 60% pre-market after a near-total wipeout? - MSN
Quince Therapeutics (QNCX) Edges Higher: Navigating Key Levels Near ResistanceCovered Call ETF - newsline.com
Quince Therapeutics Inc. (QNCX) Q1 2026 Earnings: Surprise Profitability as EPS Beats Estimates by Over 200% - thelegaladvocate.com
Deal Watch: Quince Moves Into Inhaled Respiratory Disease With Orphai Acquisition - Citeline News & Insights
Quince Therapeutics regains compliance with Nasdaq listing requirements By Investing.com - Investing.com South Africa
Quince Therapeutics regains compliance with Nasdaq listing requirements - Investing.com
Quince regains Nasdaq compliance after reporting $15.7M stockholders' equity - TradingView
[8-K] Quince Therapeutics, Inc. Reports Material Event - Stock Titan
Time is ripe for Quince with Orphai buy and $187m financing - The Pharma Letter
QNCX Stock Price, Quote & Chart | QUINCE THERAPEUTICS INC (NASDAQ:QNCX) - ChartMill
Quince Therapeutics (QNCX) Expands Pipeline with Acquisition of - GuruFocus
Quince Therapeutics (QNCX) Reveals Positive Phase 2a Results for LAM-001 - GuruFocus
Quince Therapeutics, Inc. (QNCX) OrphAI Therapeutics IncM&A CallSlideshow (NASDAQ:QNCX) 2026-05-18 - Seeking Alpha
LAM-001 trial shows gains in PH-ILD patients for Quince Therapeutics (QNCX) - Stock Titan
Quince reports phase 2a data for LAM-001 in lung disease By Investing.com - Investing.com Australia
QNCX Stock Slides As Traders React To Volatile Price Action - StocksToTrade
Quince acquires Orphai, raises $115M in private placement - Investing.com UK
Quince reports phase 2a data for LAM-001 in lung disease - Investing.com UK
Quince Therapeutics reports phase 2a data for LAM-001 in PH-ILD By Investing.com - Investing.com South Africa
Quince acquires Orphai, raises $115M in private placement By Investing.com - Investing.com South Africa
Quince Therapeutics announces LAM-001 data - TipRanks
Quince Therapeutics Closes Orphai Deal and Secures Funding - TipRanks
QNCX: Acquisition and financing secure LAM-001’s development for rare pulmonary diseases through 2028 - TradingView
UPDATEQuince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD - The Manila Times
Quince announces acquisition of Orphai and up to $187 million private placement to advance pulmonary pipeline - marketscreener.com
Quince Therapeutics Acquires Orphai and Secures $187M Financing to Advance Pulmonary Rapamycin Pipeline - Minichart
Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD - The Manila Times
Quince Therapeutics reports phase 2a data for LAM-001 in PH-ILD - Investing.com Canada
Quince Therapeutics Stock Faces Nasdaq Pressure After Fresh QNCX Filing - TechStock²
Quince Therapeutics (QNCX) acquires Orphai and secures up to $187M PIPE - Stock Titan
Press Release: Quince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipeline - Moomoo
Quince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipeline - marketscreener.com
QNCX Stock Slides As Traders Weigh Cash Runway And Volatility - timothysykes.com
Quince Therapeutics, Inc. acquired OrphAI Therapeutics Inc for $80.9 million. - marketscreener.com
Quince Therapeutics, Inc. announced that it expects to receive $115.000298 million in funding - marketscreener.com
QNCX Should I Buy - Intellectia AI
Quince Therapeutics Inc (QNCX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Quince Therapeutics Inc 주식 (QNCX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Benatti Luca | Director |
Dec 26 '25 |
Sale |
3.47 |
50,000 |
173,500 |
39,179 |
| Hannah Brendan | CBO, COO & CCO |
Dec 05 '25 |
Option Exercise |
0.91 |
27,551 |
25,012 |
361,827 |
2.60%
0.94%
자본화:
|
볼륨(24시간):